SynthesisClinical and experimental nephrology2020
Extracellular vesicles carrying miRNAs in kidney diseases: a systemic review.
Synthesis in Clinical and experimental nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficient delivery of small RNAs to podocytes in vitro by direct exosome transfection.Journal of nanobiotechnology · 2025Article
- Isolation and Characterization of Urinary Extracellular Vesicles for MicroRNA Biomarker Signature Development with Reference to MISEV Compliance.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes.Signal transduction and targeted therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
MiRNAs play essential roles in processes of physiological status and disease conditions including in renal diseases, while extracellular vesicles (EVs) serve as important mediators for cell-cell communication. In body fluid or extracellular spaces, miRNAs are packaged into EVs and transferred to targeted cells to perform their bioeffects under particular conditions. In the present review, we aim to summarize and update the known and verified EV-carrying miRNAs (EV-miRNAs) and their general roles in kidney diseases. In addition to performing a systemic analysis, we try to provide some clues and perspectives for the future study of EV-miRNAs in renal diseases.
Indexed as
Identifiers
32767135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.